Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 15:2020:5463451.
doi: 10.1155/2020/5463451. eCollection 2020.

Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis

K Daniels  1   2 , P B van der Nat  1   2 , S T F M Frequin  3 , P J van der Wees  2 , D H Biesma  1   4 , E L J Hoogervorst  3 , E M W van de Garde  5   6
Affiliations

Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis

K Daniels et al. Mult Scler Int. .

Abstract

Background: Recently, ocrelizumab (Ocrevus®) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered.

Objective: The aim of this study was to provide data about the clinical effectiveness of ocrelizumab for patients diagnosed with PPMS in a real-world setting.

Methods: We conducted a retrospective cohort study of all patients with PPMS who started ocrelizumab treatment (n = 21) in St. Antonius Hospital (Utrecht/Nieuwegein, the Netherlands) between April 2018 and December 31, 2018. Primary outcome was pre- versus post-ocrelizumab disability worsening rate (from 96 weeks prior to first ocrelizumab administration up to 24 weeks post first ocrelizumab administration).

Results: Disability worsening rate while on treatment significantly differed (lower) from disability worsening rate in pre-treatment period (Z = -2.81, p ≤ .01). Three out of 17 patients showed a clinically relevant improvement in disability status after treatment start.

Conclusion: Ocrelizumab can stabilize disability progression in patients with PPMS. Some patients even showed a clinically relevant improvement in disability status. Further research should help to identify which patients benefit most from ocrelizumab.

PubMed Disclaimer

Conflict of interest statement

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1
Figure 1
Time-to-event: 12-week confirmed disability progression of real-world pre-ocrelizumab population (n = 17) and the ORATORIO placebo arm. ORATORIO data were adapted from the original ORATORIO publication of Montalban et al. [12].
Figure 2
Figure 2
Pre- versus post-ocrelizumab disability worsening of patients diagnosed with PPMS (N = 17).
See this image and copyright information in PMC

References

    1. Sherman R. E., Anderson S. A., Dal Pan G. J., et al. Real-world evidence - what is it and what can it tell us? The New England Journal of Medicine. 2016;375(23):2293–2297. doi: 10.1056/NEJMsb1609216. - DOI - PubMed
    1. Food and Drug Administration. Use of real-world evidence to support regulatory decision-making for medical devices: draft guidance for industry and Food and Drug Administration staff. 2017. January 2019, https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance....
    1. Trojano M., Tintore M., Montalban X., et al. Treatment decisions in multiple sclerosis - insights from real-world observational studies. Nature Reviews Neurology. 2017;13(2):105–118. doi: 10.1038/nrneurol.2016.188. - DOI - PubMed
    1. Rothwell P. M. External validity of randomised controlled trials: "to whom do the results of this trial apply?". The Lancet. 2005;365(9453):82–93. doi: 10.1016/S0140-6736(04)17670-8. - DOI - PubMed
    1. Mills E. A., Begay J. A., Fisher C., Mao-Draayer Y. Impact of trial design and patient heterogeneity on the identification of clinically effective therapies for progressive MS. Multiple Sclerosis. 2018;24(14):1795–1807. doi: 10.1177/1352458518800800. - DOI - PMC - PubMed

LinkOut - more resources